Prosecution Insights
Last updated: November 20, 2026

Amy E Juedes, USPTO Patent Examiner

Listed by the USPTO as JUEDES, AMY E

Tech Center 1600 • Art Units: 1644 1675

This examiner grants 45% of resolved cases

Analysis

JUEDES, AMY E has 929 resolved cases in tech center 1600 and art unit 1644. The allowance rate is 44.8%, while the interview lift is 41.9%. The profile thus combines an allowance rate below half of resolved cases with a strong positive association between interviews and allowance outcomes, making interview strategy particularly relevant to prosecution planning.

The median time to allowance is 1388 days. The listed companies are The Trustees of the University of Pennsylvania, Sloan-Kettering Institute for Cancer Research, and Iovance Biotherapeutics Inc. The leading firms are FOLEY & LARDNER LLP, Knobbe, Martens, Olson & Bear, LLP, and LEYDIG VOIT & MAYER, LTD. These names provide practical context for applicant and counsel experience reflected in the record.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

44.8%
Allow Rate
-15.2% vs TC avg
1,004
Total Applications
+41.9%
Interview Lift
1388
Avg Prosecution Days
Based on 929 resolved cases, 2023–2026

Rejection Statute Breakdown

4.3%
§101 Eligibility
17.6%
§102 Novelty
29.1%
§103 Obviousness
31.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18587251 METHODS OF TREATING TAU PATHOLOGIES Non-Final OA Genentech, Inc.
18037514 BOVINE ANTIBODY VARIANTS Non-Final OA Zoetis Services LLC
17927072 ENHANCED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR Final Rejection Tsinghua University
14437902 METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY Final Rejection TAKEDA PHARMACEUTICAL COMPANY LIMITED
18580741 MCT11 ANTIBODIES TO TREAT T CELL FUNCTIONAL EXHAUSTION AND ENHANCE CANCER IMMUNOTHERAPY Final Rejection University of Pittsburgh - Of the Commonwealth System of Higher Education
18281471 ENGINEERED IMMUNE CELLS AND USES THEREOF Final Rejection The Johns Hopkins University
18021687 B-CELL BASED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS Final Rejection Northwestern University
18559146 INHIBITORY CHIMERIC ANTIGEN RECEPTOR PREVENTS ON-TARGET OFF-TUMOR EFFECTS OF ADOPTIVE CELL THERAPY Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18263658 IMPROVED T-CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS Non-Final OA UNIVERSITY HEALTH NETWORK
18625699 METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17735624 COMPOSITIONS AND METHODS FOR REGULATING CAR T CELLS Final Rejection The Trustees of the University of Pennsylvania
18257814 IMMUNOGENIC COMPOSITIONS Non-Final OA FRED HUTCHINSON CANCER CENTER
18429006 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS Final Rejection Iovance Biotherapeutics, Inc.
17415175 Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof Final Rejection Iovance Biotherapeutics, Inc.
18042405 STEM CELL-LIKE MEMORY T CELLS AND USES THEREOF Final Rejection GEORGETOWN UNIVERSITY
18286684 CHIMERIC CYTOKINE RECEPTORS AND USES THEREOF IN CELLULAR THERAPIES Final Rejection Nanjing Legend Biotech Co., Ltd.
18003279 IMMUNOTHERAPY Final Rejection NEOGAP THERAPEUTICS AB

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Amy E Juedes's allowance rate?

44.8% of resolved applications examined by Amy E Juedes were allowed (929 resolved cases), compared with 35.8% across Art Unit 1644 over the last five years.

Does an interview help with examiner Amy E Juedes?

This examiner's interview lift is +41.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Amy E Juedes take to allow a patent?

Applications allowed by Amy E Juedes took 1,388 days on average from filing to allowance.

Which art unit does examiner Amy E Juedes work in?

Amy E Juedes examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month